LU91072I2 - Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA - Google Patents

Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA

Info

Publication number
LU91072I2
LU91072I2 LU91072C LU91072C LU91072I2 LU 91072 I2 LU91072 I2 LU 91072I2 LU 91072 C LU91072 C LU 91072C LU 91072 C LU91072 C LU 91072C LU 91072 I2 LU91072 I2 LU 91072I2
Authority
LU
Luxembourg
Prior art keywords
inspra
eplerenone
pharmaceutically acceptable
acceptable salts
salts
Prior art date
Application number
LU91072C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU91072I2 publication Critical patent/LU91072I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LU91072C 1983-04-13 1984-04-10 Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA LU91072I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13

Publications (1)

Publication Number Publication Date
LU91072I2 true LU91072I2 (fr) 2004-04-07

Family

ID=4223123

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91072C LU91072I2 (fr) 1983-04-13 1984-04-10 Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA

Country Status (23)

Country Link
US (1) US4559332A (fr)
EP (1) EP0122232B1 (fr)
JP (1) JPS59231100A (fr)
AR (4) AR241918A1 (fr)
AT (1) ATE39256T1 (fr)
AU (1) AU565017B2 (fr)
CA (1) CA1220781A (fr)
DD (2) DD233375A5 (fr)
DE (2) DE3475622D1 (fr)
DK (1) DK163988C (fr)
ES (4) ES531517A0 (fr)
FI (1) FI77669C (fr)
GR (1) GR81834B (fr)
HU (1) HU191406B (fr)
IE (1) IE57541B1 (fr)
IL (1) IL71504A (fr)
LU (1) LU91072I2 (fr)
NL (1) NL300144I2 (fr)
NO (1) NO159800C (fr)
NZ (1) NZ207826A (fr)
PH (1) PH19997A (fr)
PT (1) PT78413B (fr)
ZA (1) ZA842710B (fr)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
DK0526642T3 (da) * 1991-01-29 1998-10-19 Shionogi & Co Triterpenderivat
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
CN1522701A (zh) * 1995-06-07 2004-08-25 G.D.ɪ����˾ 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰
WO1996040255A2 (fr) * 1995-06-07 1996-12-19 G.D. Searle & Co. Procede de traitement de la fibrose cardiaque par une combinaison therapeutique d'un antagoniste de l'angiotensine ii et d'un antagoniste de l'aldosterone epoxy-steroide
EP1170299A3 (fr) * 1995-12-11 2004-11-10 G.D. Searle & Co. Produits intermédiares pour la production des stéroides 9,11-époxy et un procédé pour leur production
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
DE69637140T2 (de) 1995-12-11 2008-04-10 G.D. Searle Llc, Chicago Verfahren zur herstellung einer epoxy-verbindung
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
DK0944644T3 (da) * 1996-12-11 2003-02-03 Searle & Co Fremgangsmåde til fremstilling af 3-keto-7-alfa-alkoxycarbonyl-delta-4,5-steroider og mellemprodukter, som er nyttite derfor
ZA9711038B (en) * 1996-12-11 1999-01-25 Searle & Co Spr process for preparation of 9,11-Epoxy steroids and intermediates useful therein
EP1148061B1 (fr) * 1996-12-11 2007-10-17 G.D. Searle LLC. Procédé d'époxydation
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
EP1000547A4 (fr) * 1998-05-29 2004-05-06 Kyowa Hakko Kogyo Kk Procede de production d'assaisonnements liquides ayant la saveur de legumes marines dans une pate de son de riz salee
BR9915134A (pt) * 1998-11-06 2001-08-07 Searle & Co Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
PT1140185E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com agentes sequestrantes de acido biliar para indicacoes cardiovasculares
ES2201822T3 (es) * 1998-12-23 2004-03-16 G.D. Searle Llc Combinaciones de inhibididores de la proteina de transferencia de ester de colesterilo y de derivados de acido nicotinico para indicaciones cardiovasculares.
WO2000038722A1 (fr) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINAISONS D'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE L'ESTER DE CHOLESTERYLE ET D'INHIBITEURS DE LA HMG CoA-REDUCTASE UTILISEES DANS LE CADRE DE TROUBLES CARDIO-VASCULAIRES
AU779264B2 (en) * 1998-12-23 2005-01-13 G.D. Searle Llc Combinations for cardiovascular indications
ES2189529T3 (es) 1998-12-23 2003-07-01 Searle Llc Combinaciones de inhiidores para el transporte de acidos biliares en el ileon y agentes complejantes para indicaciones cardiovasculares.
CA2356422C (fr) 1998-12-23 2008-09-16 G.D. Searle Llc Combinaisons d'inhibiteurs de transport de l'acide biliaire ileal et d'inhibiteurs de la proteine de transfert de l'ester de cholesteryle utilisees dans le cadre de maladies cardio-vasculaires
ATE242009T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
BR9916565A (pt) * 1998-12-23 2002-01-29 Searle Llc Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
EP1505072A3 (fr) * 1999-12-08 2006-06-21 Pharmacia Corporation Forme cristalline d'eplerenone possédant une vitesse de dissolution accrue
PT1175220E (pt) * 1999-12-08 2005-07-29 Pharmacia Corp Composicoes de eplerenona em nanoparticulas
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
CA2362845A1 (fr) * 1999-12-08 2001-06-14 Pharmacia Corporation Forme cristalline d'eplerenone
EP1527782A1 (fr) * 1999-12-08 2005-05-04 Pharmacia Corporation Compositions nanoparticulaires d'eplérenone
JP2003516414A (ja) * 1999-12-08 2003-05-13 ファルマシア コーポレイション より高い溶解速度を示すエプレレノン結晶形
US6794544B2 (en) 2000-03-10 2004-09-21 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
JP2004501099A (ja) * 2000-05-11 2004-01-15 フアルマシア　コーポレイション アルドステロン頂点位相時の放出のためのアルドステロンアンタゴニスト組成物
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
US20040235809A1 (en) * 2000-07-27 2004-11-25 Alexander John C Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure
AU2001285318A1 (en) * 2000-08-28 2002-03-13 Pharmacia Corporation Use of an aldosterone receptor antagonist to improve cognitive function
CA2427615A1 (fr) * 2000-10-30 2002-06-13 Pharmacia Corporation 11 alpha hydroxylase et oxydoreductase d'aspergillus ochraceus
KR20030057549A (ko) * 2000-11-09 2003-07-04 아스트라제네카 아베 블록 공중합체를 포함하는 경구용 약학 조성물
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP2005518347A (ja) * 2001-11-02 2005-06-23 ジー．ディー． サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
PL371128A1 (en) * 2001-12-12 2005-06-13 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
BR0306643A (pt) 2002-01-17 2004-10-19 Pharmacia Corp Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
AU2003222010A1 (en) * 2002-03-18 2003-10-08 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
US20040067918A1 (en) * 2002-03-18 2004-04-08 Keller Bradley T. Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
BR0308475A (pt) * 2002-03-20 2005-01-11 Pharmacia Corp Formulação de eplerenona estável na armazenagem
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
DK1487859T3 (da) * 2002-03-22 2008-10-06 Pharmacia & Upjohn Co Llc Fremstillingsmetoder til at fremstille Eplerenon
EP1534732B1 (fr) * 2002-08-16 2006-09-13 Pharmacia & Upjohn Company LLC Intermediaires de 5 androstene-3-ol steroides et leurs procedes de preparation
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
TW200407150A (en) * 2002-11-06 2004-05-16 Upjohn Co Processes for preparing 7- carboxy substituted steroids
WO2004043986A1 (fr) * 2002-11-07 2004-05-27 Pharmacia & Upjohn Company Llc Procedes de preparation de 5-androstenes substitues en c-7
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
KR20060123647A (ko) * 2004-03-22 2006-12-01 파마시아 앤드 업존 캄파니 엘엘씨 9,11 에폭시 스테로이드의 개선된 제조 방법
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾－4－烯－7，21－二甲酸，9，11－环氧－17－羟基－3－氧代，γ－内酯，甲酯，(7α,11α,17α)－的制备方法
WO2007025780A2 (fr) * 2005-09-02 2007-03-08 Recordati Ireland Limited Antagonistes des recepteurs de l'aldosterone
EP1842543A1 (fr) 2006-04-05 2007-10-10 Speedel Pharma AG Composition pharmaceutique comprennant un inhibiteur de l'aldosteron synthase et un antagoniste de recepteur mineralcorticoide
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
AU2007335192A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical composition
CA2582496A1 (fr) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Procede ameliore permettant la preparation et la purification de l'eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
CA2763572C (fr) 2009-05-28 2017-10-17 Novartis Ag Derives aminopropioniques substitues comme inhibiteurs de neprilysine
MA33364B1 (fr) 2009-05-28 2012-06-01 Novartis Ag Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011097571A2 (fr) * 2010-02-08 2011-08-11 Prairie Pharmaceuticals, Llc Procédé pour l'utilisation de progestogène comme sensibilisateur aux glucocorticoïdes
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
WO2011157798A1 (fr) 2010-06-16 2011-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pour stimuler la réépithélialisation durant la subérification d'une blessure
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012107513A1 (fr) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Procédé d'obtention de la drospirénone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
WO2014126979A1 (fr) 2013-02-14 2014-08-21 Novartis Ag Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
US9562068B2 (en) 2014-10-17 2017-02-07 Industriale Chimica, S.R.L. Process for the preparation of 7 α-(methoxycarbonyl)-3-OXO-17alpha-pregn-4,9(11)-dien-21,17-carbolactone, a useful intermediate for the synthesis of molecules with pharmacological activity
WO2017055248A1 (fr) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement d'une insuffisance cardiaque
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
WO2018019843A1 (fr) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur des minéralocorticoïdes pour le traitement de l'arthrose
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP4395785A1 (fr) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Méthodes de traitement de la rosacée oculaire

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
FI77669C (fi) 1989-04-10
ES8602846A1 (es) 1985-12-01
IL71504A0 (en) 1984-07-31
JPS59231100A (ja) 1984-12-25
ES531517A0 (es) 1985-12-01
NL300144I1 (nl) 2004-06-01
AU565017B2 (en) 1987-09-03
CA1220781A (fr) 1987-04-21
US4559332A (en) 1985-12-17
DE122004000012I2 (de) 2006-06-08
ES8705461A1 (es) 1987-05-01
PT78413A (en) 1984-05-01
AR242221A1 (es) 1993-03-31
PT78413B (en) 1986-08-22
IL71504A (en) 1987-07-31
GR81834B (fr) 1984-12-12
ES8705460A1 (es) 1987-05-01
AR242223A1 (es) 1993-03-31
DD251144A5 (de) 1987-11-04
NO841465L (no) 1984-10-15
NL300144I2 (nl) 2004-06-01
EP0122232A1 (fr) 1984-10-17
DD233375A5 (de) 1986-02-26
IE840906L (en) 1984-10-13
ZA842710B (en) 1984-11-28
DK163988C (da) 1992-09-21
NO159800B (no) 1988-10-31
ATE39256T1 (de) 1988-12-15
ES8705459A1 (es) 1987-05-01
HU191406B (en) 1987-02-27
FI841400A0 (fi) 1984-04-09
PH19997A (en) 1986-08-28
DK189484A (da) 1984-10-14
DK163988B (da) 1992-04-27
JPH0212479B2 (fr) 1990-03-20
AU2685384A (en) 1984-10-18
FI77669B (fi) 1988-12-30
AR242222A1 (es) 1993-03-31
NZ207826A (en) 1986-07-11
ES544770A0 (es) 1987-05-01
ES544769A0 (es) 1987-05-01
NO159800C (no) 1989-02-08
DK189484D0 (da) 1984-04-12
IE57541B1 (en) 1992-10-07
DE3475622D1 (en) 1989-01-19
DE122004000012I1 (de) 2012-05-16
EP0122232B1 (fr) 1988-12-14
AR241918A1 (es) 1993-01-29
ES544768A0 (es) 1987-05-01
FI841400L (fi) 1984-10-14

Similar Documents

Publication Publication Date Title
LU91072I2 (fr) Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
DE3464100D1 (en) Electric-cable structure and its application
IT1205010B (it) Tetraidronaftalin-derivati e indan-derivati
ES542657A0 (es) Perfeccionamientos en los aparatos de fermentacion y proce- dimiento de fermentacion correspondiente
BR1100036A (pt) Composto e composição farmacêutica
DK41484D0 (da) Beta-phenethanolaminer og deres anvendelse
DK49588A (da) Taetnings- og afstrygningsindretning
DK551187D0 (da) Terapeutisk praeparat og dettes fremstilling
DK412787D0 (da) Medicinsk-kirurgisk pose og dennes fremstilling
DK254488A (da) Azaindol- og indolizinderivater
DK210689A (da) Steroidderivater
DK553782A (da) Cyclohexyl- og phenylsubstituerede enkephaliner og deres fremstilling
DK413187A (da) Semicarbazoner og thiosemicarbazoner
DK488185D0 (da) N6-benzopyrano- og benzothiopyranoadenosiner
PT89072A (pt) Estojo estanque e impermeavel
DK422984A (da) Aminocyklopentaner og farmaceutiske praeparater deraf
DK501989D0 (da) Mikrobiocidt praeparat og dettes fremstilling
DK90591D0 (da) Beskyttelsesramme
DK162607C (da) Azopigmentpraeparater og deres anvendelse
FR2588259B1 (fr) Bis-acridiniques monopontes et bis-acridiniques bipontes
DE3475192D1 (de) Pyrrolizidinones and indolizidones
SE8304181D0 (sv) Energiforfaranden och -anordningar
DK428987D0 (da) En fallelaas
SE8504463D0 (sv) Dosier- und appliziervorrichtung